Latest News about Fda
Recent news which mentions Fda
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
From Benzinga
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug
September 18, 2024
From Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
September 18, 2024
From Benzinga
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
September 16, 2024
From Benzinga
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
September 16, 2024
From Benzinga
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
September 16, 2024
From Benzinga
From Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
September 11, 2024
From Benzinga
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
September 10, 2024
From Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
From Benzinga
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
September 09, 2024
From Benzinga
FDA Rejection Of MDMA Could Fuel Black Market Demand, Warns CEO Of Women's Psychedelic Platform SetSet
September 07, 2024
From Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
From Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
From Benzinga
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
September 05, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.